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Background: The Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efﬁcacy (CD PROBE;
NCT00836017) is a prospective, observational, multicenter, real-world registry designed to assess the safety,
effectiveness, and treatment utilization following multiple treatments of onabotulinumtoxinA.
Methods: Subjects were naïve to botulinum toxin, new to practice, or had not received toxin in≥16 weeks if in a
clinical trial. Dosages and treatment intervals varied due to the real-world design. Descriptive and inferential
statistics evaluated changes over 3 treatments.
Results: 1046 subjects enrolled. Subjects were 74.4% female, 63.5% toxin-naïve, mean age 58.0 ± 14.7 years.
The mean dose over 2481 treatment sessions was 189.8 ± 87.1 U, with average treatment intervals of 14.6
and 15.1 weeks. The mean Toronto Western Spasmodic Torticollis Rating Scale Total score in subjects who
completed all assessments (n = 479) decreased from 39.2 at baseline to 27.1 at ﬁnal visit (P b .0001). A high
percentage of physicians reported improvement in Clinician Global Impression of Change after initial assess-
ment; this signiﬁcantly increased at ﬁnal assessment (n = 479, 91.2% vs 95.0%; P b .0001). Similarly, a high
percentage of subjects reported improvement in Patient Global Impression of Change after initial assessment,
which signiﬁcantly increased at ﬁnal assessment (n = 470, 83.0% vs 91.7%; P b .0001). Signiﬁcant reductions
in all Cervical Dystonia Impact Proﬁle-58 scores were observed (n = 407). Overall, 26.2% of subjects reported
adverse events, including muscular weakness (7.0%) and dysphagia (6.4%).
Conclusions: Results indicate robust improvement in clinical ratings and excellent tolerability following
onabotulinumtoxinA treatment of CD.© 2014 Elsevier B.V. All rights reserved.1. Introduction
Cervical dystonia (CD), the most common form of focal dystonia, is
manifested by involuntarymuscular contractions, resulting in abnormal
head and shouldermovements and/or postures that can involve tremor
and pain [1,2]. Several studies have demonstrated that CD can be poten-
tially stigmatizing and has a negative impact on quality of life (QOL)
[3–5]. Botulinum toxin (BoNT) is considered the treatment of choice
for CD [6,7]. Although its safety and efﬁcacy have been well established
by controlled clinical trials [8,9], there are few long-term studies toepartment of Neurology, Smith
Tel.: +1 713 798 7438; fax:+1determine the impact of BoNT treatments on QOL and other outcome
measures in real-world practice.
Evidence-based practice is strongly encouraged and increasingly
mandated by regulatory agencies and payer policies. While placebo-
controlled trials remain the gold standard in assessing response to a
therapeutic intervention, they often involve a relatively homogenous
population of patients with pre-speciﬁed duration of symptoms, age,
comorbidities, and restricted concomitant medications. Furthermore,
placebo-controlled trials are usually short-term and are not suitable to
determine long-term efﬁcacy and safety. Observational studies are
designed to address such concerns, and if designed to collect data in a
pre-speciﬁed fashion, may provide important insight into the effects
of medical treatments on disease state [10,11].
The Cervical Dystonia Patient Registry for Observation of
OnabotulinumtoxinA Efﬁcacy (CD PROBE) is an observational,
Fig. 1. Study design of CD PROBE and timing of physician- and subject-reported assessments. Abbreviations: AE, adverse event; CD, cervical dystonia; CDIP-58, Cervical Dystonia Impact
Proﬁle-58; CGIC, Clinician Global Impression of Change; PGIC, Patient Global Impression of Change; PNRS, Pain Numeric Rating Scale; TWSTRS, Toronto Western Spasmodic Torticollis
Scale. Fig. 1 is reprinted with permission from Jankovic J, Adler CH, Charles PD, et al. Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of
OnaBotulinumtoxinA Efﬁcacy (CD PROBE). BMC Neurol. 2011;11:140. Copyright 2011 BMC Neurology.
85J. Jankovic et al. / Journal of the Neurological Sciences 349 (2015) 84–93multicenter, prospective clinical registry designed to describe cur-
rent treatment practices and summarize the safety and effectiveness
proﬁle, including QOL outcomes, for onabotulinumtoxinA treatment
of CD [12]. This is the ﬁrst report of primary outcomes in CD PROBE.
2. Methods
2.1. Study design and subjects
Full methods, including detailed descriptions of inclusion and exclu-
sion criteria, of CD PROBE (ClinicalTrials.gov identiﬁer: NCT00836017)
have been previously described [12]. Brieﬂy, subjects diagnosedFig. 2. Subject dwith CD were identiﬁed by the enrolling physician as candidates
for onabotulinumtoxinA therapy. Participants also had to meet ≥1
of the following criteria: new to the physician practice, new to
BoNT therapy, and/or if previously treated with BoNT in a clinical
trial, must not have received BoNT for ≥16 weeks. CD PROBE com-
plied with the ethical principles described in the current revision of
the Declaration of Helsinki. Institutional review boards reviewed
the study protocol and the informed consent form prior to initiating
the study. Informed consent was obtained for each subject. The study
size was determined as the number of subjects who could be reason-
ably recruited at the 88 US sites within the enrollment time frame of
January 12, 2009 to August 31, 2012.isposition.
Table 2
Summary of treatment characteristics for each session and overall.
Treatment
session 1
(n = 1041)
Treatment
session 2
(n = 804)
Treatment
session 3
(n = 636)
Overall
(N = 2481)
Total number of
injections, n
86 J. Jankovic et al. / Journal of the Neurological Sciences 349 (2015) 84–93Enrolled subjects could receive up to 3 onabotulinumtoxinA
(BOTOX®, Allergan, Inc., Irvine, CA, USA) treatment sessions: at base-
line/visit 1, visit 2, and visit 3 (Fig. 1). Treatment interval, dilution, dos-
ing, injection guidance, andmuscles injected with onabotulinumtoxinA
were at the full discretion of the treating physician. Phone interviews
were conducted 4–6 weeks post-injection, and the time to the next
treatment session was determined by standard of care at eachMean ± SD 8.7 ± 5.2 9.5 ± 5.8 10.0 ± 6.2 9.3 ± 5.7
Range 1.0–45.0 1.0–41.0 0.0–40.0 0.0–45.0
Total number of
muscles injected
Mean ± SD 4.0 ± 1.4 4.1 ± 1.5 4.3 ± 1.5 4.1 ± 1.4
Range 0.0–11.0 1.0–11.0 0.0–13.0 0.0–13.0
Total dose, U
Mean ± SD 171.6 ±
78.9
199.6 ±
88.3
207.2 ±
93.0
189.8 ±
87.1
Range 15.0–500.0 20.0–517.7 25.0–519.5 15.0–519.5
Data not available, n 64 49 37 150
Dilution, n (%)
1 mL/100 U vial 681 (69.7) 538 (71.3) 424 (70.8) 1643 (70.5)
2 mL/100 U vial 257 (26.3) 187 (24.8) 146 (24.4) 590 (25.3)
Other 39 (4.0) 30 (4.0) 29 (4.8) 98 (4.2)
Data not available, n 64 49 37 150
Injection guidance,
n (%)
Anatomicala 269 (25.8) 217 (27.0) 174 (27.4) 660 (26.6)
Electromyography 772 (74.2) 585 (72.8) 459 (72.4) 1816 (73.3)
Ultrasound 0 (0) 0 (0) 0 (0) 0 (0)
Other 0 (0) 2 (0.2) 1 (0.2) 3 (0.1)
Data not available, n 0 0 2 2
Muscle injected, n (%)
Splenius capitus 901 (86.6) 683 (85.0) 551 (86.6) 2135 (86.1)
Sternocleidomastoid 788 (75.7) 621 (77.2) 499 (78.5) 1908 (76.9)
Levator scapulae 693 (66.6) 543 (67.5) 433 (68.1) 1669 (67.3)
Trapezius 654 (62.8) 517 (64.3) 407 (64.0) 1578 (63.6)
Scalenes 319 (30.6) 268 (33.3) 227 (35.7) 814 (32.8)
Semispinalis 299 (28.7) 236 (29.4) 199 (31.3) 734 (29.6)
Longissimus 188 (18.1) 148 (18.4) 128 (20.1) 464 (18.7)
Splenius cervicis 107 (10.3) 80 (10.0) 67 (10.5) 254 (10.2)
Otherb 187 (18.0) 230 (28.6) 225 (35.4) 642 (25.9)
a Inspection and palpation.
b Includes muscles written in by physician (cervical paraspinal muscles, corrugator
supercilii, frontalis, masseter, obliquus capitis inferior muscle, pectoralis, platysma,
procerus, rhomboids, suboccipitalis, and temporalis); each was b10%.
Table 1
Baseline subject demographics and disease characteristics.
Overall
N = 1041
Demographics
Age, years 58.0 ± 14.7
Gender, n (%)
Female 774 (74.4)
Race, n (%)
White 961 (92.3)
Non-white 80 (7.7)
Employment status, n (%)
Retired 340 (32.7)
Employed full time 311 (29.9)
Employed part time 67 (6.4)
Disabled 123 (11.8)
Self-employed 61 (5.9)
Othera 139 (13.4)
Educational level, n (%)
High school or less 357 (34.3)
Any college 519 (49.9)
Advanced degree 147 (14.1)
Other 17 (1.6)
Data not available, n 1
Clinical characteristics
Predominant subtype, n (%)
Anterocollis 59 (5.7)
Laterocollis 404 (38.9)
Retrocollis 55 (5.3)
Torticollis 494 (47.5)
Other 27 (2.6)
Data not available, n 2
Severity, n (%)
Mild 345 (33.2)
Moderate 548 (52.7)
Severe 146 (14.1)
Data not available, n 2
Age at symptom onset, years 49.0 ± 16.7
Time from CD onset to diagnosis, years 5.0 ± 8.1
Time from diagnosis to treatment, years 1.1 ± 4.5
Prior treatment with botulinum toxin, n (%)
Yes 380 (36.5)
No 661 (63.5)
Common comorbid conditions, n (%)
Unspeciﬁed essential hypertension 340 (32.7)
Depressive disorder not elsewhere classiﬁed 207 (19.9)
Pure hypercholesterolemia 164 (15.8)
Anxiety state unspeciﬁed 125 (12.0)
Esophageal reﬂux 121 (11.6)
Unspeciﬁed acquired hypothyroidism 111 (10.7)
Other and unspeciﬁed hyperlipidemia 97 (9.3)
Migraine 95 (9.1)
Unspeciﬁed arthropathy 67 (6.4)
Parkinson's disease 60 (5.8)
Concomitant medications, n (%)
Vitamins and combinations 373 (35.8)
Analgesics, miscellaneous 230 (22.1)
Antilipidemic agents, HMG-CoA reductase inhibitors 168 (16.1)
Antidepressants, selective serotonin reuptake inhibitors 162 (15.6)
β-adrenergic blocking agents 154 (14.8)
Thyroid preparations 139 (13.4)
Antianxiety agents, benzodiazepines and combinations 131 (12.6)
Antidepressants, miscellaneous 123 (11.8)
Proton pump inhibitors 119 (11.4)
All values are means with standard deviation unless stated otherwise.
a Other includes homemaker, never employed, student, and unemployed.
Table 3
Treatment paradigm.
Total subjects
(N = 1041)
Total treatment sessions
(N = 2481)
Dose, U
≤100 315 (31.8) 486 (20.8)
101–200 631 (63.7) 1085 (46.5)
201–300 344 (34.7) 566 (24.3)
N300 108 (10.9) 176 (7.6)
Data not available, n 50 150
Injection sites
b7 510 (49.0) 957 (38.6)
7–12 585 (56.2) 1032 (41.6)
N12 253 (24.3) 492 (19.8)
Injected muscles
b3 176 (16.9) 297 (12.0)
3–5 866 (83.2) 1839 (74.1)
N5 196 (18.8) 345 (13.9)
Dosing interval, weeks
b11 38 (4.7) 46 (3.2)
N13 627 (78.0) 879 (61.0)
N16 207 (25.7) 246 (17.1)
Data are presented as n (%). Groups are not mutually exclusive because a patient could be
represented more than once.
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vals, varied due to the real-world design. Visit 4 was the ﬁnal ofﬁce
visit and did not include a treatment.
Treatment data were veriﬁed throughout the study. Missing or
inconsistent data were queried and corrected by the sites as
needed. Additional monitoring was conducted after entry of all
data and focused on high- (≥600 U) and low- (b50 U) dose
outliers.2.2. Outcome variables
Baseline information collected prior to initial study treatment at visit
1 included demographic information, history of CD diagnosis and past
treatments, physician classiﬁcation of predominant CD subtype and
severity, comorbidities, and concomitant medications. Investigators
also answered a questionnaire that included type of practice and receipt
of formal BoNT training.
For this primary analysis, effectiveness assessments included the
TorontoWestern Spasmodic Torticollis Rating Scale (TWSTRS), Clinician
and Patient Global Impression of Change (CGIC and PGIC, respectively)
and the Cervical Dystonia Impact Proﬁle-58 (CDIP-58) (Fig. 1).
TWSTRS, a validated, widely used rating scale for CD [13,14], was
assessed at baseline, treatment session 3, and ﬁnal ofﬁce visit. The
TWSTRS Total score is the sum of the 3 subscales: Severity, Disability,
and Pain; higher scores indicate greater impairment [15]. The CGIC is a
7-item scale ranging from “very much improved” to “very much
worse,” in which the physician assesses clinically meaningful change
in the health of the subject since the start of study treatment [16].
CGIC was assessed at treatment sessions 2 and 3 and ﬁnal ofﬁce visit.
The PGIC is 7-item scale, similar to the CGIC, in which the subject as-
sesses the change in his/her health status since the start of study treat-
ment and provides insight into value of treatment to the subject [17].
PGIC was assessed at each ofﬁce visit and phone interview except at
baseline/visit 1. The CDIP-58, assessed at each ofﬁce visit and phone in-
terview, is a validated, disease-speciﬁc, QOL questionnaire that can
measure the impact of BoNT treatment in CD [14,18,19]. It consists of
58 questions comprising 8 subscales, with higher scoresmore impaired.
Safety was evaluated by reported adverse events (AEs), each
assessed by the investigator regarding severity (mild, moderate, se-
vere), treatment relatedness, and whether it was serious. At each ofﬁce
visit, the physician answered the question “Has the patient experienced
any adverse events since the last registry visit?” All AEs were coded
using theMedical Dictionary for Regulatory Activities, version 13.1 [20].2.3. Statistical analyses
Descriptive statistics were utilized to deﬁne the sociodemographics
and disease characteristics and to analyze treatment patterns. Descrip-
tive and inferential statistics, analysis of variance (ANOVA), and analysis
of covariance (ANCOVA) were used when appropriate to evaluate any
change in outcome measures over study treatment sessions. Data
were generated for 2 subpopulations: (1) the as-treated population,
comprised of subjects who completed the ﬁrst treatment session and
reported whether they were naïve or non-naïve to BoNT treatment at
baseline (N = 1041), and (2) the subset of the as-treated population
who completed all assessments for a given measure (numbers vary by
outcome measures). A P value of ≤ .05 was considered statistically
signiﬁcant within the subpopulation with complete data.
AEs were reported per rates of total population and per total AEs.
AE incidence rate was calculated as: ([total unique events] ×
[365.25 days per year]) / sum of exposure time in days, where the
time of exposure for each subject was the time from enrollment
until the latest of the available dates of treatment, peak effect contact,
or withdrawal.3. Results
3.1. Subject disposition
The as-treated population included those who reported whether
they had prior exposure to BoNT and completed the ﬁrst treatment ses-
sion (N = 1041); 5 subjects enrolled but did not receive treatment
(Fig. 2). Of the enrolled subjects, 60.8% (n= 636) completed all 3 treat-
ment sessions, and 48.0% (n= 502) completed all 3 treatment sessions
and the ﬁnal assessment visit; 410 subjects withdrew before the ﬁnal
visit.
Of the enrolled subjects, 22.8% withdrew after the ﬁrst visit, 20.9%
after the second, and 21.1% after the third (Fig. 2). The most common
reasons for discontinuation were loss to follow-up (n = 243, 23.2%),
consent withdrawal (n = 95, 9.1%), lack of response after any of the 3
treatment sessions (n = 85, 8.1%), and AE (n = 32, 3.1%).
Comparison of the demographics and baseline disease characteris-
tics between those who discontinued for any reason and those who
completed the study indicated that the demographic proﬁles were sim-
ilar. There were no signiﬁcant differences across the 2 groups in
TWSTRS, physician assessment of severity, predominant subtype of
CD, or whether they had received BoNT in the past. The Head and
Neck subscale of the CDIP-58 was signiﬁcantly higher at baseline in
those who completed the study compared with those who withdrew
(71.7 vs 68.4, respectively; P = .0079). In addition, the total dose at
treatment session 1 was signiﬁcantly higher for those who completed
compared with those who withdrew (178.4 U vs 165.5 U; P= .0108).
Those who completed the study were more likely to have been treated
by an investigator with formal BoNT training compared with those who
withdrew (96.2% vs 92.5%; P= .0118).
3.2. Baseline demographics and disease characteristics
Themean age of the 1041 as-treated subjects was 58.0± 14.7 years;
74.4% were female (Table 1). The mean time from diagnosis to treat-
ment was 1.1 ± 4.5 years. The most predominant postures were torti-
collis (47.5%) and laterocollis (38.9%), and 63.5% of subjects were
toxin-naïve at baseline. Over half of subjects' CD (52.7%) was rated as
moderately severe.
Out of 85 responding treating physicians in CD PROBE, 76 (89.4%)
were neurologists, 8 (9.4%) were physical medicine and rehabilitation
physicians, and 1 (1.2%)was a pain specialist.Most (91.7%) had received
formal BoNT training.
3.3. Treatment characteristics and paradigm
Data from 2481 onabotulinumtoxinA treatment sessions were cap-
tured (Table 2). The mean total dose across all 3 treatment sessions
was 189.8 ± 87.1 U and ranged from 15 to 519.5 U. Mean doses
increased over the treatment sessions (171.6 U, 199.6 U, and 207.2 U
for sessions 1–3, respectively). Similarly, the mean number of total
injections increased from 8.7 ± 5.2 to 10.0 ± 6.2 over treatment ses-
sions 1–3. About 70% of treatment sessions utilized the 1mL/100U dilu-
tion of onabotulinumtoxinA, and in about 75% of treatment visits,
electromyography was used to guide the injection into the intended
target muscle. The mean time between treatments increased from
14.6 ± 4.1 weeks following treatment session 1 to 15.1 ± 5.2 weeks
after treatment session 2.
Doses of b50 U, considered low-dose outliers, were administered to
19 subjects over 25 treatment sessions. All doses b50Uwere veriﬁed by
the study site; 19/25 of these doses were administered at the same
center. When examining treatment interval outliers, 7 subjects had
treatment intervals b60 days (5, 26, 34, 36, 51, 53, and 56 days, respec-
tively). Only 2 of the 7 subjects with short treatment intervals were
administered low doses (30 U, 50 U).
88 J. Jankovic et al. / Journal of the Neurological Sciences 349 (2015) 84–93Examination of the treatment paradigm showed that the majority
of subjects (63.7%) received 101–200 U, and 31.8% (n = 315) of sub-
jects received a dose ≤100 U. Most subjects (56.2%) received 7–12A
B
Cinjections per treatment session, which most commonly involved
3–5 muscles (83.2%). Additionally, most subjects (78.0%) and treat-
ment sessions (61.0%) had a treatment interval of N13 weeks. Less
DFig. 3.Effectiveness assessments fromCDPROBE for subjectswith complete data for eachassessment. (A) TorontoWestern Spasmodic Torticollis Rating Scale (n=479), (B) ClinicalGlobal
Impression of Change (n = 479), (C) Patient Global Impression of Change (n = 470), and (D) Cervical Dystonia Impact Proﬁle-58 (n = 407). Abbreviations: BL, baseline; CD PROBE,
Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efﬁcacy; CI, conﬁdence interval; dot, mean; line in box, median; PI, phone interview; top and bottom of box,
interquartile range; V, visit; whiskers, minimum and maximum. (A). n = 479 for all visits. Scales range as follows: Severity, 0–35; Disability, 0–30; Pain, 0–20; and Total, 0–85.
*P b .0001 vs baseline. (B). n = 479 for all visits. *P b .0001 vs visit 2. (C). n = 470 for all visits. *P b .0001 vs phone interview 1. †P b .01 vs phone interview 1. (D). n = 407 for all visits.
Data are mean ± 95% CI. Scores for each domain range from 0 to 100. *P b .0001 vs baseline.
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b11 weeks (Table 3).
3.4. Effectiveness outcomes
There was a signiﬁcant and sustained improvement in all TWSTRS
domains after onabotulinumtoxinA treatments (Fig. 3A). When evalu-
ating the subpopulation of subjects who completed all TWSTRS assess-
ments (n= 479), the mean TWSTRS total score signiﬁcantly decreased
from a baseline score of 39.2 to 27.1 at ﬁnal assessment (P b .0001)
(Fig. 3A). Furthermore, each TWSTRS subscale signiﬁcantly decreased
from baseline to ﬁnal visit (each P b .0001). Improvements were
sustained over time. Results were similar to those from the as-treated
population: mean TWSTRS total score of 38.8 at baseline (visit 1),
31.5 at visit 3, and 27.1 at ﬁnal visit (Fig. 4A).
In the subpopulation of subjectswith all CGIC assessments (n=479),
a signiﬁcantly higher percentage of physicians reported subject CD as
minimally, much, or very much improved at ﬁnal visit compared with
visit 2; 95.0% vs 91.2%, respectively (P b .0001) (Fig. 3B). Results were
similar to those from the as-treated population: at visit 2, 89.5% of physi-
cians rated subject CD as minimally, much, or very much improved,
which increased to 93.5% at visit 3 and 94.8% at the ﬁnal assessment
(Fig. 4B). Similarly, when evaluating the subpopulation of subjects who
had all PGIC assessments (n = 470), a signiﬁcantly higher percentage
of subjects reported improvement at ﬁnal visit compared with phone
interview 1: 91.7% vs 83.0% of subjects reported CD symptoms asminimally, much, or very much improved (P b .0001) (Fig. 3C). Results
were similar to those from the as-treated population (Fig. 4C).
Among the CDIP-58 domains, the Head and Neck and Pain and
Discomfort subscale scores were the highest (i.e., most impacted) at
baseline (Fig. 3D). Signiﬁcant reductions in all CDIP-58 subscale scores
were observed following onabotulinumtoxinA treatment for the
subpopulation with complete data (n = 407) and were sustained over
time (each P b .0001) (Fig. 3D). Head and Neck subscale scores de-
creased from 71.1 at baseline to 50.3 at ﬁnal visit; Pain and Discomfort,
70.8 to 51.9; Upper Limb Activities, 50.9 to 41.1; Walking, 43.4 to 35.1;
Sleep, 55.7 to 39.9; Annoyance, 57.7 to 39.8; Mood, 49.2 to 35.3; and
Psychosocial, 53.7 to 38.6 (each P b .0001). Formost subscales, improve-
ments were most robust at phone interviews (peak effect) and slightly
decreased prior to the next treatment session. Similar results were
observed in the as-treated population (Fig. 4D).
3.5. Safety outcomes
A total of 515 AEs were reported in 273 (26.2%) unique subjects
(Table 4). The overall incidence rate of AEs was 0.6 per subject per
year. Most AEs (88.3%, n = 455) were mild to moderate in severity.
Muscular weakness (n=9) and dysphagia (n=7)were themost com-
mon AEs in those who withdrew due to AE. AEs reported in ≥2.0% of
subjects were muscular weakness (7.0%), the majority of which were
local; dysphagia (6.4%; of which 2.8% was moderate to severe); and
neck pain (2.7%).
90 J. Jankovic et al. / Journal of the Neurological Sciences 349 (2015) 84–93There were 315 treatment-related AEs reported in 185 subjects
(17.8%). The most common events were muscular weakness (6.9%), dys-
phagia (6.2%), and neck pain (2.3%). There were 46 serious AEs (SAEs)A
B
Creported in 33 subjects (3.2%), with an overall incidence of 0.1 per subject
per year. Four treatment-related SAEs were reported in 4 subjects (0.4%).
Four deathswere reported; nonewere considered to be treatment-related.
DFig. 4. As-treated data for effectiveness assessments from CD PROBE. (A) TorontoWestern Spasmodic Torticollis Rating Scale, (B) Clinical Global Impression of Change, (C) Patient Global
Impression of Change, and (D) Cervical Dystonia Impact Proﬁle-58. Abbreviations: BL, baseline; CD PROBE, Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA
Efﬁcacy; dot, mean; line in box, median; PI, phone interview; top and bottom of box, interquartile range; V, visit; whiskers, minimum and maximum. (A). n = 1038 for baseline (visit
1), n = 635 for visit 3, and n = 480 for ﬁnal visit (visit 4). Scales range as follows: Severity, 0–35; Disability, 0–30; Pain, 0–20; and Total, 0–85. (B). n = 799 for visit 2, n = 634 for
visit 3, and n = 483 for ﬁnal visit (visit 4). (C). n = 959 for phone interview 1, n = 800 for visit 2, n = 717 for phone interview 2, n = 633 for visit 3, and n = 504 for ﬁnal visit (visit
4). (D). n = 1037 for baseline (visit 1), n = 953 for phone interview 1, n = 797 for visit 2, n = 716 for phone interview 2, n = 632 for visit 3, and n = 502 for ﬁnal visit (visit 4). Scores
for each domain range from 0 to 100.
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CD PROBE, with 1046 subjects enrolled by 88 investigators and data
from2481 treatment sessions, was designed and implemented to assess
the safety and effectiveness of BoNT in patientswith CD. This real-world
information on treatment outcomes provides support for the conclu-
sion that onabotulinumtoxinA signiﬁcantly and safely decreases CD
symptoms and improves QOL of patients with CD. OnabotulinumtoxinA
appears to be well tolerated, and no new safety concerns emerged.
Baseline demographics of subjects were similar to those of subjects
in other large trials [8,21–25]. Baseline TWSTRS Total scoreswere slight-
ly lower in CD PROBE compared with those from registration trials
for other BoNTs (mean of 39.2 in CD PROBE and low to mid-40s for
registration trials) [21–24].
Although the mean onabotulinumtoxinA doses increased over
the treatment sessions from 171.6 U to 207.2 U, the mean dose of
189.8 ± 87.1 U is lower than the maximum recommended dose [26],
is comparable to the mean dose of 187.0 ± 76.5 U in another observa-
tional study [9], and is less than doses previously reported as typical in
clinical practice [7]. This is possibly because 63.5% were BoNT-naïve.
Consistent with other longitudinal studies, the treatment interval also
increased with subsequent treatment sessions [27].
CDPROBE aimed to represent the “real-world” experience and reﬂects
a broad range of treatment practices. As a result, outliers were identiﬁed.
For example, the few cases of low doses and short treatment intervals
may be due to physicians testing tolerability to onabotulinumtoxinA,since these were mostly observed during the ﬁrst treatment session.
Some practitioners may have used “touch-up” sessions, whereby a low
dose of onabotulinumtoxinA was injected into a speciﬁc area to optimize
beneﬁt, thus accounting for the short treatment interval in limited cases.
Such “booster” injections are generally not recommended, as this practice
has been associated with increased risk of immunoresistance [27].
In CD PROBE, onabotulinumtoxinA treatment showed signiﬁcant
and sustained improvements in CD symptoms, as measured via both
physician- and subject-reported outcomes, including TWSTRS, CGIC,
PGIC, and CDIP-58. There is no deﬁned minimal important difference
(MID) for TWSTRS [10], but BoNT trials have deﬁned a responder as a
subject with a decrease in the TWSTRS Total score of ≥30% and/or
≥10 points [21,25]. In CD PROBE, the mean change in TWSTRS Total
score from baseline to ﬁnal visit was 12.1, which is 30.9% lower than
the baseline score (median change from baseline to ﬁnal visit is 14.0, a
35.9% reduction). The CDIP-58 also has no deﬁned MID [10], but the
changes from baseline to peak effect for each subscale in CD PROBE
were comparable to or better than those in a smaller clinical trial [19].
We recognize that the frequency of discontinuations (n = 544,
52.0%) was relatively high, which reduced the sample size available
for outcome-related analyses. This is, however, not entirely unexpected,
as CD PROBE is an observational, naturalistic study rather than a ran-
domized clinical trial. Registries generally have higher discontinuation
rates than randomized clinical trials, as these studies often enroll a
broader subject population, have a longer study duration, and do not
have a protocol-deﬁned treatment schedule [11]. Registries also do
Table 4
Subject- and event-based adverse events.
Event, n (%) Subjects
N = 1041
Events
Overall AEs 273 (26.2) 515 (100.0)
Muscular weakness 73 (7.0) 87 (16.9)
Dysphagia 67 (6.4) 77 (15.0)
Neck pain 28 (2.7) 31 (6.0)
Headache 16 (1.5) 20 (3.9)
Injection site pain 13 (1.2) 13 (2.5)
Musculoskeletal pain 10 (1.0) 11 (2.1)
Treatment-related AEs 185 (17.8) 315 (61.2)
Muscular weakness 72 (6.9) 86 (16.7)
Dysphagia 65 (6.2) 75 (14.6)
Neck pain 24 (2.3) 26 (5.0)
Headache 11 (1.1) 14 (2.7)
Injection site pain 12 (1.2) 12 (2.3)
Serious AEs 33 (3.2) 46 (8.9)
Cardiac arrest 3 (0.3) 3 (0.6)
Chest pain 2 (0.2) 2 (0.4)
Convulsion 2 (0.2) 2 (0.4)
Dysphagia 2 (0.2) 2 (0.4)
Hip fracture 2 (0.2) 2 (0.4)
Loss of consciousness 2 (0.2) 2 (0.4)
Orthostatic hypotension 2 (0.2) 2 (0.4)
Pyrexia 2 (0.2) 2 (0.4)
Syncope 2 (0.2) 2 (0.4)
Urinary tract infection 2 (0.2) 2 (0.4)
Treatment-related SAEs 4 (0.4) 4 (0.8)
Dysphagia 2 (0.2) 2 (0.4)
Chest pain 1 (0.1) 1 (0.2)
Respiratory distress 1 (0.1) 1 (0.2)
Overall and treatment-related AEs in ≥1.0% of subjects, SAEs in N1 subject, and all
treatment-related SAEs are presented.
Abbreviations: AE, adverse event; SAE, serious adverse event.
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ﬁnancial challenges thatmay adversely impact retention. In comparison
to CD PROBE's retention rate (48.0% of subjects completed the study),
72–96% of subjects in the BoNT registration trials completed the respec-
tive studies [8,21–24], with the exception of 1 trial in which 26.3% of
subjects remained in the study after week 12 [25]. The retention rate
in CD PROBE was lower than those of other registries, which range
from 65.4 to 77.5% [28,29]. We performed additional analyses in order
to better understand the reasons for discontinuation and the potential
impact on the study conclusions. Most (110/134) of the subjects who
withdrew between treatment session 3 and ﬁnal visit were lost to
follow-up; this accounts for almost half of those who were lost to
follow-up over the entire course of the study. Therefore, 60.8% com-
pleted all 3 treatment cycles. We hypothesize that the high rates of
withdrawal prior to the ﬁnal visit may have been due to subject unwill-
ingness to take the time for a non-treatment ofﬁce visit, particularly
since it was the ﬁnal visit for the study. The high withdrawal rate,
one of the major limitations of our study, could have been possibly
prevented if we had offered treatment at the fourth visit as an incentive
to the subjects to return for this last visit. This issue should be taken into
account for the design of future studies. Although the baseline charac-
teristics of those who completed the study were similar to those who
discontinued early, the former group may have been slightly more se-
vere as suggested by higher CDIP-58 Head and Neck subscale score
and higher total dose at treatment session 1,whichmayhave compelled
them to remain in the study.
Although the ﬁndings should be interpreted cautiously because of
the open-label design and relatively high discontinuation rate, the
strength of CD PROBE is that it is a large clinical registry of
prospectively followed subjects that provides data on the clinical nu-
ances of treatment that are not generally obtainable from
randomizedcontrolled trials. The results conﬁrm the robust efﬁcacy
and safety of onabotulinumtoxinA in the treatment of CD.
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